ICICI Prudential Nifty Pharma Index Fund - Growth
Category: Index Fund
Launch Date: 14-12-2022
AUM:
₹ 84.27 Cr
Expense Ratio
0.98%
Benchmark
NIFTY Pharma TRI
ISIN
INF109KC18L6
Minimum Investment
1000.0
Minimum Topup
1000.0
Minimum SIP Amount
1000
Fund Manager
Nishit Patel
| Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
|---|---|---|---|
| ICICI Prudential Nifty Pharma Index Fund - Growth | 10.32 | - | - |
| Nifty Pharma TRI | 12.36 | 21.89 | 17.97 |
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
Overview
NAV
16.7254
Last change
0.04 (0.2386%)
Fund Size (AUM)
₹ 84.27 Cr
Performance
23.09% (Inception)
Asset Allocation
Equity
Debt
Others
Nav Movement
Investment Objective
The objective of the Scheme is to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index. However, there is no assurance or guarantee that the investment objective of the scheme shall be achieved.
Fund Manager
Nishit Patel
Riskometer
Very High
Top 10 Holdings
| Company | Holdings (%) |
|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 23.72 |
| DIVIS LABORATORIES LIMITED EQ NEW RS. 2/- | 11.01 |
| CIPLA LIMITED EQ NEW FV RS.2/- | 10.81 |
| Dr. Reddys Laboratories Ltd | 10.01 |
| LUPIN LIMITED EQ NEW F.V. RS.2/- | 6.2 |
| TORRENT PHARMACEUTICALS LIMITED EQ NEW FV RS.5/- | 4.35 |
| AUROBINDO PHARMA LIMITED EQ NEW F.V. RE.1/- | 4.21 |
| MANKIND PHARMA LIMITED EQ NEW FV RE. 1/- | 3.65 |
| ALKEM LABORATORIES LIMITED EQ | 3.55 |
| LAURUS LABS LIMITED EQ NEW FV RS. 2/- | 3.13 |
Sector Allocation
| Sector | Holdings (%) |
|---|---|
| Healthcare | 99.91 |
| N/A | 0.09 |